pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

Lancet series highlights men’s health paradox and rising urgent-care costs

Oct 30, 2026·read at STAT ↗Negative

The Lancet has launched a new series examining why men consistently experience poorer health outcomes than women despite advantages in certain areas.

The series points to gaps in research, screening, and treatment that leave men at higher risk for conditions such as cardiovascular disease, mental health disorders, and certain cancers.

In a related health‑policy note, the newsletter cites a private‑equity‑backed urgent‑care network, Intuitive Health, where patients with simple issues like urinary tract infections are being billed at emergency‑room rates, sometimes approaching $2,000.

These high charges illustrate broader systemic issues that disproportionately affect men, who already face barriers to preventive care and timely diagnosis.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “The persisting paradox of men’s health”

read at STAT ↗
1,365 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Dana-Farber Cancer Institute IncNational Institutes of HealthProtara Therapeutics, Inc.UNIQUE
drugs
EPINEPHRINEEPIPEN E Z PEN
topics
Oncology11Colorectal Cancer8Psychiatry & CNS3Breast CancerCardiologyInfectious DiseaseMicrobiomeVaccine

related stories

  • Dec 22Fierce Biotech Fundraising Tracker '26: Nouscom nabs $135M series D; Estuary channels $93M series AFierce Biotech
  • 37m agoImmutep, Molecular cut workforcesBioSpace
  • 4d agoA virus that afflicts cows makes the jump to a humanSTAT
  • Sep 1Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?Fierce Biotech
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive